PMID- 26521884
OWN - NLM
STAT- MEDLINE
DCOM- 20161019
LR  - 20231111
IS  - 2212-4063 (Electronic)
IS  - 0929-8673 (Print)
IS  - 1871-529X (Linking)
VI  - 15
IP  - 3
DP  - 2016
TI  - A Pilot Study to Assess Adenosine 5'-triphosphate Metabolism in Red Blood Cells 
      as a Drug Target for Potential Cardiovascular Protection.
PG  - 224-32
AB  - OBJECTIVE: To study the effect of exercise preconditioning on adenosine 
      5'triphosphate (ATP) metabolism in red blood cells and cardiovascular protection 
      against injury induced by isoproterenol in vivo. METHODS: Male Sprague Dawley 
      rats (SDR) were each exercised on a treadmill for 15 minutes at 10 m/min and 10% 
      grade (n = 7) (LowEx), or 14 m/min and 22% grade (n = 8) (VigEx). Two hours after 
      the exercise, each rat received a single dose of isoproterenol (30 mg/kg) by 
      subcutaneous (sc) injection. Two separate groups of SDR were used as control: One 
      received no exercise (n = 10) (NoEx) and the other received no exercise and no 
      isoproterenol (n = 11) (NoIso). Serial blood samples were collected over 5 hours 
      for measurement of ATP and its catabolites by a validated HPLC. Hemodynamic 
      recording was collected continuously for the duration of the experiment. Data 
      were analysed using ANOVA and t-tests and difference considered significant at p 
      < 0.05. RESULTS: Exercise pre-conditioning (both LowEx and VigEx) reduced 
      mortality after isoproterenol from 50% to < 30% (p > 0.05). It attenuated the 
      rebound in blood pressure significantly (p < 0.05 between NoEx vs VigEx), 
      attenuated the increase of RBC adenosine 5'-monophosphate (AMP) concentrations 
      induced by isoproterenol, and also decreased the breakdown of ATP to AMP in the 
      RBC (p < 0.05 vs NoEx). CONCLUSION: Exercise pre-conditioning decreased the blood 
      pressure rebound and also breakdown of ATP in RBC after isoproterenol which may 
      be exploited further as a drug target for cardiovascular protection and 
      prevention.
FAU - Yeung, Pollen K F
AU  - Yeung PK
AD  - College of Pharmacy and Department of Medicine, Dalhousie University, Halifax, 
      NS, Canada B3H 4R2. Pollen.Yeung@Dal.Ca.
FAU - Tinkel, Jodi
AU  - Tinkel J
FAU - Seeto, Dena
AU  - Seeto D
LA  - eng
GR  - ROP86932/Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Cardiovasc Hematol Disord Drug Targets
JT  - Cardiovascular & hematological disorders drug targets
JID - 101269160
RN  - 0 (Cardiotonic Agents)
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - L628TT009W (Isoproterenol)
SB  - IM
MH  - Adenosine Triphosphate/*metabolism
MH  - Animals
MH  - Blood Pressure/drug effects
MH  - Cardiotonic Agents/administration & dosage/*pharmacology
MH  - Erythrocytes/*drug effects/metabolism
MH  - Isoproterenol/administration & dosage/*pharmacology
MH  - Male
MH  - Molecular Targeted Therapy
MH  - Physical Conditioning, Animal
MH  - Pilot Projects
MH  - Rats, Sprague-Dawley
PMC - PMC4997928
EDAT- 2015/11/03 06:00
MHDA- 2016/11/12 06:00
PMCR- 2016/08/25
CRDT- 2015/11/03 06:00
PHST- 2015/09/01 00:00 [received]
PHST- 2015/09/10 00:00 [revised]
PHST- 2015/10/28 00:00 [accepted]
PHST- 2015/11/03 06:00 [entrez]
PHST- 2015/11/03 06:00 [pubmed]
PHST- 2016/11/12 06:00 [medline]
PHST- 2016/08/25 00:00 [pmc-release]
AID - CHDDT-EPUB-71503 [pii]
AID - CHDDT-15-224 [pii]
AID - 10.2174/1871529x15666151102102702 [doi]
PST - ppublish
SO  - Cardiovasc Hematol Disord Drug Targets. 2016;15(3):224-32. doi: 
      10.2174/1871529x15666151102102702.